Crystalline Memantine Derivative Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Memantine, a treatment for neurodegenerative diseases, faces challenges due to its high water solubility and adverse effects such as confusion, dizziness, and hallucinations, limiting its therapeutic use.
Innovation Solution
Development of crystalline forms of the memantine derivative ((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate, specifically Forms I and II, with improved solubility and stability, characterized by distinct X-ray powder diffraction patterns and differential scanning calorimetry thermograms, which are used in pharmaceutical compositions to treat central nervous system diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If memantine is used to treat neurodegenerative diseases, then therapeutic effects are achieved, but high water solubility causes formulation challenges and adverse effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of memantine through derivatization. Specifically, compound (I) introduces a carbamoyl group and ester functionality, changing the molecular parameters (adding polar groups) to improve water solubility while maintaining the adamantane core structure responsible for NMDA receptor antagonism. This structural parameter modification resolves the contradiction by enabling better solubility without sacrificing therapeutic efficacy.
Solution Approach 2:
The patent creates a composite molecular structure combining the hydrophobic adamantane core with hydrophilic functional groups (carbamoyl and ester groups). This composite approach integrates both lipophilic and hydrophilic characteristics, allowing the molecule to maintain membrane permeability while achieving improved water solubility, thereby reducing formulation challenges and potential adverse effects.
2Quantity of substance
If high water solubility is achieved, then bioavailability may improve, but formulation challenges increase
Solution Approach 1:
The patent modifies the solubility parameter of memantine by introducing hydrophilic functional groups (carbamoyl at position 1 and ester group). This parameter change increases water solubility from the original memantine's limited solubility, while the controlled modification maintains manageable formulation characteristics through predictable physicochemical properties.
3Stability of the object's composition
If crystalline forms are developed, then stability and solubility are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by creating specific localized crystalline arrangements (polymorphs) with distinct molecular packing patterns. Crystalline Form I and Form II represent different local organizational patterns of the same molecule in the solid state, each with optimized properties for stability and solubility while maintaining manufacturability through defined crystal structures.
Data Source
AI summary
Provided herein are crystalline forms of (((((1r, 3R, 5S, 7r)-3, 5-dimethyladamantan-1-yl)carbamoyl) oxy) methyl benzoate (Compound (I)): Also provided are compositions comprising the crystalline forms of Compound (I), processes of manufacture and methods of using the crystalline forms of Compound (I).